🔎 Trials Near Me

ホーム › バーキットリンパ腫

米国で参加者を募集しているバーキットリンパ腫の臨床試験

米国全土の拠点で、バーキットリンパ腫に関する63件の研究が参加者を募集しています。

最も多くの研究がある都市

州別

最近更新された研究

公式研究テキスト（英語）

Blinatumomab Consolidation in Real World

被験者募集中観察研究健康なボランティア歓迎
18歳以上 · 全性別 · 2026/10/01更新 · NCT07117136

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

被験者募集中第2相
366 Days – 46 Years · 全性別 · 2026/10/01更新 · NCT06124157

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

被験者募集中第1/2相
3歳〜39歳 · 全性別 · 2026/09/30更新 · NCT05442515

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

被験者募集中第2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT03739814

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

被験者募集中第1/2相
18歳〜120歳 · 全性別 · 2026/09/28更新 · NCT03223610

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06144606

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

被験者募集中第2相
365 Days · 全性別 · 2026/09/25更新 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07648264

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

被験者募集中第3相
1歳以上 · 全性別 · 2026/09/17更新 · NCT07223021

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

被験者募集中第1/2相
6 Months – 25 Years · 全性別 · 2026/09/17更新 · NCT06395103

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

被験者募集中第1相
0歳〜18歳 · 全性別 · 2026/09/16更新 · NCT06173518

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

被験者募集中第1/2相
31 Days – 30 Years · 全性別 · 2026/09/14更新 · NCT04544592

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/08更新 · NCT03666000

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

被験者募集中第3相
18歳〜39歳 · 全性別 · 2026/09/02更新 · NCT03150693

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

被験者募集中第2相
1歳〜30歳 · 全性別 · 2026/09/01更新 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

被験者募集中第3相
365 Days – 25 Years · 全性別 · 2026/08/25更新 · NCT03959085

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

被験者募集中第1相
18歳〜120歳 · 全性別 · 2026/08/25更新 · NCT05389423

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

被験者募集中第2相
7歳〜25歳 · 全性別 · 2026/08/19更新 · NCT05082519

Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia

被験者募集中
18歳以上 · 全性別 · 2026/08/19更新 · NCT06710418

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

被験者募集中第1/2相
12歳以上 · 全性別 · 2026/08/19更新 · NCT06137118

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

被験者募集中第1相
18歳以上 · 全性別 · 2026/08/12更新 · NCT06340737

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

被験者募集中第2相
15歳以上 · 全性別 · 2026/08/10更新 · NCT03136146

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06287229

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

被験者募集中第1相
18歳〜81歳 · 全性別 · 2026/08/06更新 · NCT05990465

ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。